Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics. Its lead product candidate is PF582, a biosimilar candidate to Lucentis that is in Phase Ib/IIa trials in patients with wet age-related macular degeneration.
Pfenex Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.